Research Use Only: This product is supplied for laboratory research and in-vitro studies. Not for human or veterinary administration.
Hover to zoom
Identity Verified: LC-MS
(0 Reviews)
Tirzepatide (30mg)
- First-in-Class Dual GIP/GLP-1 Agonist: 39-amino acid synthetic peptide (LY3298176), Eli Lilly design, imbalanced dual agonism (GIPR>GLP-1R), biased GLP-1R signaling (cAMP>beta-arrestin), 3,000+ publications, ~5-day half-life via C20 fatty diacid albumin binding
- Unprecedented Metabolic Effects: HbA1c reduction 1.24-2.58%, 22.5% mean weight loss at 15mg (SURMOUNT-1), weight-independent insulin sensitization via GIPR, BCAA catabolism, central appetite suppression
- Clinical Status: FDA-approved Mounjaro (T2D, May 2022), Zepbound (obesity, Nov 2023), OSA (Dec 2024); SURPASS-CVOT 38% reduction CV death/HF events, SYNERGY-NASH 73.3% MASH resolution
- Mechanistic pathway studies
- In vitro receptor profiling
- HPLC verified identity and purity
$199.00In Stock
Ships same-day if ordered before 2PM EST
1
Encrypted Checkout
Global Express
Research Overview
Tirzepatide (30mg) - Dual Incretin Receptor Agonist Research Peptide Molecular Profile: Tirzepatide is a revolutionary 39-amino acid dual GIPR/GLP-1R agonist ("twincretin") based on native GIP sequence with strategic modifications. Molecular formula C₂₂₅H₃₄₈N₄₈O₆₈, molecular weight 4,813.5 Da, CAS 2023788-19-2. Key modifications: α-aminoisobutyric acid (Aib) at positions 2 and 13 for DPP-4 resistance; C20 eicosanedioic acid at Lys20 via γGlu-OEG-OEG linker for albumin binding and ~5-day half-life enabling once-weekly dosing. Mechanism of Action: Tirzepatide's imbalanced dual agonism provides high GIPR affinity (matching native GIP) with intentionally reduced GLP-1R affinity (5-20x lower), optimizing therapeutic window by minimizing GI side effects while maximizing metabolic benefits. Demonstrates biased GLP-1R agonism favoring cAMP signaling over β-arrestin. Synergistic GIPR + GLP-1R activation produces superior glycemic control (HbA1c -2.58%) and weight loss (>20%) vs single-target agents. Research Applications: This 30mg format is designed for extended longitudinal studies, dose-escalation protocols, and comprehensive dual incretin receptor research. Product Specifications: - Purity: ≥95% (HPLC verified) - Form: Lyophilized powder - Content: 30 mg net peptide per vial - Storage: -20°C, protected from light and moisture - Certificate of Analysis provided Laboratory Use Only: This product is intended strictly for in-vitro research applications. NOT FOR HUMAN CONSUMPTION. FDA-approved drug substance (Mounjaro/Zepbound). Intended for qualified researchers only.
This product is intended exclusively for in vitro laboratory research by qualified professionals. Not for human consumption. Not approved by the FDA.
Published Research Briefs
Our research team has published evidence-checked briefs covering the science behind this compound. Each brief reviews primary sources and grades claims independently.